TAK-994 (Ox2R agonist) ✔️

Takeda Pharmaceuticals

Confirmed correct on March 31, 2023 in Ishikawa et al. in J. Pharm Exp. Ther. (2023).

TAK-994 is an oral orexin 2 receptor (OxR2) agonist developed by Takeda Pharmaceuticals (TAK 0.00%↑) for the treatment of narcolepsy. This compound was in phase 2 (NCT04820842) before development was discontinued in 2021 due to liver toxicity.